On September 9, CSPC PHARMA fell 3.03% in regular trading, trading at HK$9.14/share, with turnover of HK$389 million. The decline came amid a broad global equity market correction that weighed heavily on Hong Kong-listed pharmaceutical stocks.

On the news front, major European indices opened lower while Japanese and Korean markets posted consecutive losses, fueling risk-off sentiment that spilled into Hong Kong. Within the sector, China Biopharmaceutical fell 1.88% and HUTCHMED declined 1.09%, reflecting broad-based pressure on drug makers.

At the company level, CSPC PHARMA has seen a dense stream of positive catalysts in recent sessions. On September 8, the company announced its novel eye drop SYH2083 received clinical trial approval for dry eye disease. On September 7, its EGFR ADC candidate SYS6010 was included in the breakthrough therapy designation list for the fourth time, and its influenza drug SYH2085 officially entered Phase II trials. Multiple investment banks maintained buy ratings with target prices ranging from HK$11.2 to HK$14, suggesting no fundamental deterioration behind the pullback.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)